Titan Pharmaceuticals Stock Price, News & Analysis (NASDAQ:TTNP)

$1.08 0.00 (0.00 %)
(As of 02/18/2018 04:00 PM ET)
Previous Close$1.08
Today's Range$1.04 - $1.10
52-Week Range$1.00 - $3.95
Volume103,308 shs
Average Volume103,031 shs
Market Capitalization$22.79 million
P/E Ratio-1.58
Dividend YieldN/A
Beta1.24

About Titan Pharmaceuticals (NASDAQ:TTNP)

Titan Pharmaceuticals, Inc. (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. The Company's segment is engaged in the development of pharmaceutical products. The Company's product development programs utilize its long-term drug delivery platform, ProNeura. The Company's drug candidate, Probuphine, is being developed for the long-term maintenance treatment of opioid dependence. Titan's ProNeura continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The Company focuses on developing two product development programs, the first one with a ropinirole implant for the treatment of Parkinson's disease (PD) and the second one with a Triiodothyronine (T3) implant for the treatment of hypothyroidism.

Receive TTNP News and Ratings via Email

Sign-up to receive the latest news and ratings for TTNP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biopharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TTNP
CUSIPN/A
Phone650-244-4990

Debt

Debt-to-Equity Ratio1.67%
Current Ratio6.12%
Quick Ratio6.12%

Price-To-Earnings

Trailing P/E Ratio-1.58088235294118
Forward P/E Ratio-1.60
P/E GrowthN/A

Sales & Book Value

Annual Sales$15.06 million
Price / Sales1.51
Cash Flow$0.26 per share
Price / Cash4.14
Book Value$0.62 per share
Price / Book1.73

Profitability

Trailing EPS($0.68)
Net Income$5.13 million
Net Margins-6,757.29%
Return on Equity-146.81%
Return on Assets-96.32%

Miscellaneous

Employees14
Outstanding Shares21,200,000

Titan Pharmaceuticals (NASDAQ:TTNP) Frequently Asked Questions

What is Titan Pharmaceuticals' stock symbol?

Titan Pharmaceuticals trades on the NASDAQ under the ticker symbol "TTNP."

How were Titan Pharmaceuticals' earnings last quarter?

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) posted its earnings results on Thursday, November, 9th. The specialty pharmaceutical company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by $0.04. The specialty pharmaceutical company earned $0.04 million during the quarter, compared to the consensus estimate of $0.17 million. Titan Pharmaceuticals had a negative return on equity of 146.81% and a negative net margin of 6,757.29%. View Titan Pharmaceuticals' Earnings History.

Where is Titan Pharmaceuticals' stock going? Where will Titan Pharmaceuticals' stock price be in 2018?

1 Wall Street analysts have issued twelve-month target prices for Titan Pharmaceuticals' stock. Their predictions range from $2.00 to $2.00. On average, they expect Titan Pharmaceuticals' share price to reach $2.00 in the next twelve months. View Analyst Ratings for Titan Pharmaceuticals.

Who are some of Titan Pharmaceuticals' key competitors?

Who are Titan Pharmaceuticals' key executives?

Titan Pharmaceuticals' management team includes the folowing people:

  • Marc Rubin M.D., Executive Chairman of the Board (Age 62)
  • Sunil Ramraje Bhonsle, President, Director (Age 65)
  • Rajinder Kumar, Director (Age 62)
  • Scott A. Smith, Director (Age 55)
  • Joseph A. Akers, Independent Director (Age 69)
  • Eurelio M. Cavalier, Independent Director (Age 82)
  • M. David David MacFarlane Ph.D., Independent Director (Age 74)

Who owns Titan Pharmaceuticals stock?

Titan Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (2.60%) and Millennium Management LLC (0.60%). Company insiders that own Titan Pharmaceuticals stock include James R Mcnab, Joseph A Akers and Sunil Bhonsle. View Institutional Ownership Trends for Titan Pharmaceuticals.

Who sold Titan Pharmaceuticals stock? Who is selling Titan Pharmaceuticals stock?

Titan Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC. View Insider Buying and Selling for Titan Pharmaceuticals.

Who bought Titan Pharmaceuticals stock? Who is buying Titan Pharmaceuticals stock?

Titan Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought Titan Pharmaceuticals stock in the last two years include James R Mcnab, Joseph A Akers and Sunil Bhonsle. View Insider Buying and Selling for Titan Pharmaceuticals.

How do I buy Titan Pharmaceuticals stock?

Shares of Titan Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Titan Pharmaceuticals' stock price today?

One share of Titan Pharmaceuticals stock can currently be purchased for approximately $1.08.

How big of a company is Titan Pharmaceuticals?

Titan Pharmaceuticals has a market capitalization of $22.79 million and generates $15.06 million in revenue each year. The specialty pharmaceutical company earns $5.13 million in net income (profit) each year or ($0.68) on an earnings per share basis. Titan Pharmaceuticals employs 14 workers across the globe.

How can I contact Titan Pharmaceuticals?

Titan Pharmaceuticals' mailing address is 400 OYSTER POINT BLVD SUITE 505, SAN FRANCISCO CA, 94080. The specialty pharmaceutical company can be reached via phone at 650-244-4990.


MarketBeat Community Rating for Titan Pharmaceuticals (TTNP)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  70 (Vote Outperform)
Underperform Votes:  51 (Vote Underperform)
Total Votes:  121
MarketBeat's community ratings are surveys of what our community members think about Titan Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Titan Pharmaceuticals (NASDAQ:TTNP) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 2.002.002.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $2.00$2.00$2.00$6.00
Price Target Upside: 25.00% upside25.00% upside25.00% upside287.10% upside

Titan Pharmaceuticals (NASDAQ:TTNP) Consensus Price Target History

Price Target History for Titan Pharmaceuticals (NASDAQ:TTNP)

Titan Pharmaceuticals (NASDAQ:TTNP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/10/2017Roth CapitalDowngradeBuy -> Neutral$6.00 -> $2.00N/AView Rating Details
(Data available from 2/18/2016 forward)

Earnings

Titan Pharmaceuticals (NASDAQ:TTNP) Earnings History and Estimates Chart

Earnings by Quarter for Titan Pharmaceuticals (NASDAQ:TTNP)

Titan Pharmaceuticals (NASDAQ TTNP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2017Q3 2017($0.16)($0.20)$0.17 million$0.04 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.14)($0.17)$0.10 million$0.08 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.15)($0.16)$0.09 million$0.04 millionViewN/AView Earnings Details
3/16/2017Q4 2016($0.12)($0.15)$0.62 million$0.04 millionViewN/AView Earnings Details
11/9/2016Q316($0.11)($0.12)$0.25 million$0.03 millionViewListenView Earnings Details
8/9/2016Q2 2016$0.60$0.55$15.00 million$15.00 millionViewN/AView Earnings Details
5/10/2016Q116($0.12)($0.09)ViewListenView Earnings Details
3/15/2016Q415($0.10)($0.11)ViewListenView Earnings Details
11/16/2015Q3 2015($0.13)($0.09)ViewN/AView Earnings Details
8/13/2015($0.02)($0.02)$0.86 million$0.76 millionViewN/AView Earnings Details
5/13/2015($0.03)($0.04)$0.66 million$0.91 millionViewN/AView Earnings Details
3/31/2015($0.01)($0.01)$0.91 million$0.91 millionViewN/AView Earnings Details
11/13/2014($0.02)($0.01)$0.90 million$0.91 millionViewN/AView Earnings Details
8/13/2014($0.02)($0.01)$0.90 million$0.91 millionViewN/AView Earnings Details
5/14/2014Q1 2014($0.11)$0.90 million$0.91 millionViewN/AView Earnings Details
11/15/2013Q3 13($0.01)$2.20 million$2.20 millionViewN/AView Earnings Details
8/14/2013Q2 2013$0.06$0.33$3.80 million$2.20 millionViewN/AView Earnings Details
5/15/2013Q1 2013($0.06)($0.17)$3.80 million$5.17 millionViewN/AView Earnings Details
11/12/2012Q3 2012($0.22)($0.66)ViewN/AView Earnings Details
8/10/2012Q2 2012($0.28)($0.15)ViewN/AView Earnings Details
5/11/2012Q1 2012($2.20)($0.48)ViewN/AView Earnings Details
3/16/2012Q4 2011($0.33)($0.27)ViewN/AView Earnings Details
11/15/2011Q3 2011($0.33)($0.08)ViewN/AView Earnings Details
8/16/2011Q2 2011($0.33)($0.65)ViewN/AView Earnings Details
5/16/2011Q1 2011($0.44)ViewN/AView Earnings Details
3/24/2011Q4 2010($0.29)ViewN/AView Earnings Details
11/15/2010Q3 2010($0.03)ViewN/AView Earnings Details
8/16/2010Q2 2010($0.17)ViewN/AView Earnings Details
5/17/2010Q1 2010($0.03)ViewN/AView Earnings Details
11/10/2008Q3 2008($0.55)($0.56)ViewN/AView Earnings Details
8/12/2008Q2 2008($0.61)($0.73)ViewN/AView Earnings Details
5/12/2008Q1 2008($0.54)ViewN/AView Earnings Details
3/12/2008Q4 2007($0.74)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Titan Pharmaceuticals (NASDAQ:TTNP) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.67 EPS
Next Year EPS Consensus Estimate: $-0.53 EPS

Dividends

Dividend History for Titan Pharmaceuticals (NASDAQ:TTNP)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Titan Pharmaceuticals (NASDAQ TTNP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.10%
Institutional Ownership Percentage: 8.89%
Insider Trades by Quarter for Titan Pharmaceuticals (NASDAQ:TTNP)
Institutional Ownership by Quarter for Titan Pharmaceuticals (NASDAQ:TTNP)

Titan Pharmaceuticals (NASDAQ TTNP) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/19/2016Joseph A AkersDirectorBuy13,000$4.85$63,050.008,000View SEC Filing  
7/18/2016Sunil BhonsleCEOBuy10,000$4.96$49,600.00135,578View SEC Filing  
5/31/2016James R McnabDirectorBuy20,000$7.03$140,600.00View SEC Filing  
2/22/2016Sunil BhonsleCEOBuy11,763$3.56$41,876.28125,578View SEC Filing  
1/15/2016Sunil BhonsleCEOBuy5,841$2.72$15,887.52113,815View SEC Filing  
1/13/2016James R McnabDirectorBuy16,363$3.16$51,707.08View SEC Filing  
1/11/2016Marc RubinChairmanBuy5,000$3.25$16,250.00156,317View SEC Filing  
1/11/2016Sunil BhonsleCEOBuy17,000$3.18$54,060.00107,974View SEC Filing  
9/16/2015Sunil BhonslePresidentBuy10,000$0.70$7,000.00491,500View SEC Filing  
8/28/2015Marc RubinChairmanBuy50,000$0.72$36,000.00832,200View SEC Filing  
8/25/2015Sunil BhonslePresidentBuy50,000$0.70$35,000.00481,500View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Titan Pharmaceuticals (NASDAQ TTNP) News Headlines

Source:
DateHeadline
Titan Announces Amendment To Horizon Loan AgreementTitan Announces Amendment To Horizon Loan Agreement
finance.yahoo.com - February 12 at 9:41 AM
Titan (TTNP) Negotiating with Braeburn for ProbuphineTitan (TTNP) Negotiating with Braeburn for Probuphine
finance.yahoo.com - February 1 at 3:54 PM
Titan In Discussions With Braeburn Regarding US Probuphine® Commercialization - PR Newswire (press release)Titan In Discussions With Braeburn Regarding US Probuphine® Commercialization - PR Newswire (press release)
www.prnewswire.com - January 24 at 8:22 AM
Titan In Discussions With Braeburn Regarding U.S. Probuphine® CommercializationTitan In Discussions With Braeburn Regarding U.S. Probuphine® Commercialization
finance.yahoo.com - January 22 at 9:50 AM
What Should Investors Know About Titan Pharmaceuticals Inc’s (NASDAQ:TTNP) Growth?What Should Investors Know About Titan Pharmaceuticals Inc’s (NASDAQ:TTNP) Growth?
finance.yahoo.com - January 6 at 9:21 AM
ETFs with exposure to Titan Pharmaceuticals, Inc. : December 26, 2017ETFs with exposure to Titan Pharmaceuticals, Inc. : December 26, 2017
finance.yahoo.com - December 26 at 12:47 PM
ETFs with exposure to Titan Pharmaceuticals, Inc. : December 11, 2017ETFs with exposure to Titan Pharmaceuticals, Inc. : December 11, 2017
finance.yahoo.com - December 11 at 3:30 PM
Titan Pharmaceuticals Inc (TTNP.OQ)Titan Pharmaceuticals Inc (TTNP.OQ)
www.reuters.com - December 6 at 11:45 AM
Is There Now An Opportunity In Titan Pharmaceuticals Inc (TTNP)?Is There Now An Opportunity In Titan Pharmaceuticals Inc (TTNP)?
finance.yahoo.com - December 5 at 11:19 AM
Titan Pharmaceuticals, Inc. (TTNP) Forecasted to Earn FY2019 Earnings of ($0.27) Per ShareTitan Pharmaceuticals, Inc. (TTNP) Forecasted to Earn FY2019 Earnings of ($0.27) Per Share
www.americanbankingnews.com - December 2 at 12:58 AM
ETFs with exposure to Titan Pharmaceuticals, Inc. : November 30, 2017ETFs with exposure to Titan Pharmaceuticals, Inc. : November 30, 2017
finance.yahoo.com - November 30 at 3:31 PM
Titan Pharma (TTNP) Enters Pact with Molteni to Market Probuphine in EuropeTitan Pharma (TTNP) Enters Pact with Molteni to Market Probuphine in Europe
www.streetinsider.com - November 29 at 3:31 PM
Titan Pharmaceuticals, Inc. :TTNP-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017Titan Pharmaceuticals, Inc. :TTNP-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
finance.yahoo.com - November 29 at 10:59 AM
Titan Pharmaceuticals Partners With Molteni To Market Probuphine® In EuropeTitan Pharmaceuticals Partners With Molteni To Market Probuphine® In Europe
finance.yahoo.com - November 28 at 8:31 AM
Titan Pharma (TTNP) Granted European Medicines Agency ... - StreetInsider.comTitan Pharma (TTNP) Granted European Medicines Agency ... - StreetInsider.com
www.streetinsider.com - November 27 at 3:20 PM
European Medicines Agency Accepts Titan Pharmaceuticals Marketing Authorization Application For Probuphine®European Medicines Agency Accepts Titan Pharmaceuticals' Marketing Authorization Application For Probuphine®
finance.yahoo.com - November 27 at 9:06 AM
Titan Pharmaceuticals reports 1Q lossTitan Pharmaceuticals reports 1Q loss
marketbeat.com - May 10 at 7:28 AM
FDA Approves New Opioid Addiction Treatment Tech - BenzingaFDA Approves New Opioid Addiction Treatment Tech - Benzinga
www.benzinga.com - May 27 at 9:49 PM
FDA Approves Titan Pharmas (TTNP) Buprenorphine Implant for Treatment of Opioid Dependence - StreetInsider.comFDA Approves Titan Pharma's (TTNP) Buprenorphine Implant for Treatment of Opioid Dependence - StreetInsider.com
www.streetinsider.com - May 26 at 9:34 PM
The First Implant to Treat Opioid Addiction Just Got ApprovedThe First Implant to Treat Opioid Addiction Just Got Approved
fortune.com - May 26 at 6:47 PM
After-Hours Stock Movers 05/23: (AGLE) (PLCM) (NDSN) Higher; (SSW) (WMGI) (BAH) Lower (more...)After-Hours Stock Movers 05/23: (AGLE) (PLCM) (NDSN) Higher; (SSW) (WMGI) (BAH) Lower (more...)
www.streetinsider.com - May 24 at 2:06 AM
TITAN PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD DisclosureTITAN PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure
biz.yahoo.com - May 19 at 6:13 AM
TITAN PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly ReportTITAN PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - May 10 at 1:43 PM
Q1 2016 Titan Pharmaceuticals Inc Earnings Release - Time Not SuppliedQ1 2016 Titan Pharmaceuticals Inc Earnings Release - Time Not Supplied
biz.yahoo.com - May 10 at 7:07 AM
TITAN PHARMACEUTICALS INCTITAN PHARMACEUTICALS INC
www.finanznachrichten.de - May 4 at 9:58 PM
Titan Pharma to Present Phase 3 Data of Probuphine at ASAM Annual Conference - BenzingaTitan Pharma to Present Phase 3 Data of Probuphine at ASAM Annual Conference - Benzinga
www.benzinga.com - April 15 at 10:55 PM
TITAN PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and ExhibitsTITAN PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - February 22 at 6:04 AM

SEC Filings

Titan Pharmaceuticals (NASDAQ:TTNP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Titan Pharmaceuticals (NASDAQ:TTNP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Titan Pharmaceuticals (NASDAQ TTNP) Stock Chart for Sunday, February, 18, 2018

Loading chart…

This page was last updated on 2/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.